Compare NWTG & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWTG | ACXP |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 6.2M |
| IPO Year | 2022 | 2021 |
| Metric | NWTG | ACXP |
|---|---|---|
| Price | $0.92 | $1.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | $4.50 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 219.0K | 77.5K |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.09 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,135,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $104.02 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 136.14 | N/A |
| 52 Week Low | $0.70 | $1.07 |
| 52 Week High | $1.94 | $7.54 |
| Indicator | NWTG | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 42.26 | 34.05 |
| Support Level | $0.78 | N/A |
| Resistance Level | $1.17 | $1.75 |
| Average True Range (ATR) | 0.15 | 0.06 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 24.55 | 24.48 |
Newton Golf Co Inc is a technology-forward golf company engaged in designing, manufacturing, and selling performance golf equipment, including premium golf shafts and putters, and focuses on developing technology-driven golf products intended to enhance player performance. The company sells its products through e-commerce, distributors, wholesale customers, including pro-shops at golf courses and off-course retailers, sporting goods retailers, online retailers, third-party distributors, and through Club Champion Golf.
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.